Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight: A Multicenter Cross-sectional Observational Study
Sponsor: AryoGen Pharmed Co.
Summary
This is a cross-sectional, observational, multi-center study to assess the prevalence of inhibitor development in hemophilia A patients receiving Coageight (rFVIII-Fc, AryoGen Pharmed Co.).
Official title: A Cross-sectional, Observational, Multi-center Study to Assess the Prevalence of Inhibitor Development in Hemophilia A Patients Receiving Coageight (rFVIII-Fc, Manufactured by AryoGen Pharmed Co.)
Key Details
Gender
MALE
Age Range
2 Years - Any
Study Type
OBSERVATIONAL
Enrollment
262
Start Date
2026-08-23
Completion Date
2027-02-20
Last Updated
2026-08-28
Healthy Volunteers
Not specified
Conditions
Interventions
efmoroctocog alfa
This study assesses patients with a history of at least 10 exposure days (EDs) to recombinant factor VIII with Fc fusion (Coageight) within the 12 months prior to enrollment.
Locations (6)
Shahid Baqaei 2 Hospital
Ahvāz, Ahvaz, Iran
Seyyed al-Shohada Hospital
Isfahan, Isfahan, Iran
Soroor Clinic
Mashhad, Mashhad, Iran
Shahid Ayatollah Dastgheib Hospital
Shiraz, Shiraz, Iran
Imam Khomeini Hospital
Tehran, Tehran Province, Iran
Mofid Children's Hospital
Tehran, Tehran Province, Iran